Pneumococcal infections - Pipeline Insight, 2022
Description
Pneumococcal infections - Pipeline Insight, 2022
DelveInsight’s, Pneumococcal infections - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Pneumococcal infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Pneumococcal infections: Overview
Streptococcus pneumoniae is a gram-positive, lancet-shaped bacterium and a cause of community-acquired pneumonia. Pneumococcal infections are present throughout the world and are most prevalent during the winter and early spring months. Community-acquired pneumonia (CAP) is the seventh leading cause of death in the United States, and the cost of these hospitalizations is estimated to cost up to $9 billion in the United States (US) dollars each year. Thirty-day hospital mortality associated with CAP has been estimated to be as high as 22% and is the leading cause of death amongst all infectious diseases.
Infection typically occurs after the colonization of the oropharynx and nasopharynx of healthy individuals. Inhalation of these colonies causes the infection of the lower airways. Infection, typically will not result unless a patient has predisposed risk factors, a bolus of infectious cells or due to a particularly virulent strain of S. pneumoniae.
The capsule plays a major role in the pathogenesis of Streptococcus pneumoniae. It is made up of polysaccharides and surrounds the cell wall. It helps in escaping phagocytosis by preventing the access of granulocytes to the underlying cell wall. These polysaccharides of the capsule help in the identification and serotyping of the bacteria. Many serotypes have been detected, 6, 14, 18, 19 and 23 are the most common ones causing the infection. On culture media, the virulence of these strains can be identified by their appearance, opaque and transparent types. Transparent type usually colonizes in nasopharynx while the opaque type is present in the lung, brain and bloodstream infection.
""Pneumococcal infections - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pneumococcal infections pipeline landscape is provided which includes the disease overview and Pneumococcal infections treatment guidelines. The assessment part of the report embraces, in depth Pneumococcal infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pneumococcal infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
DWN12088: Daewoong Pharmaceutical
DWN12088 is an investigational therapy for idiopathic pulmonary fibrosis (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body’s ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein’s sequence. The FDA designated it as an orphan drug for idiopathic pulmonary fibrosis (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.
AFX3772: Affinivax
AFX3772, is a lead vaccine candidate targeting Streptococcus pneumoniae, includes 24 pneumococcal polysaccharides, more than any other vaccine on the market, as well as two conserved pneumococcal proteins. Developed using Affinivax’s proprietary MAPS™ (Multiple Antigen-Presenting System) technology platform, AFX3772 is designed to elicit both B-cell (antibody) and T-cell immune protection against Streptococcus pneumoniae. Company expect a Phase III clinical trial in older adults to begin in 2022. The clinical program targeting the infant pneumococcal indication has been initiated with an ongoing Phase 1 study in healthy toddlers 12 to 15 months of age.
PnuBioVax: ImmBio
nuBioVax, a vaccine targeting pneumococcal disease. This project, initiated with funding from the UK’s Biomedical Catalyst, has provided strong evidence of cross-strain efficacy beyond current vaccines. PnuBioVax has now progressed into full Clinical Development with the completion of a Phase I Clinical Trial.
Further product details are provided in the report……..
Pneumococcal infections: Therapeutic Assessment
This segment of the report provides insights about the Pneumococcal infections drugs segregated based on following parameters that define the scope of the report, such as:
Pneumococcal infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pneumococcal infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pneumococcal infections drugs.
Pneumococcal infections Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, Pneumococcal infections - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Pneumococcal infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pneumococcal infections: Overview
Streptococcus pneumoniae is a gram-positive, lancet-shaped bacterium and a cause of community-acquired pneumonia. Pneumococcal infections are present throughout the world and are most prevalent during the winter and early spring months. Community-acquired pneumonia (CAP) is the seventh leading cause of death in the United States, and the cost of these hospitalizations is estimated to cost up to $9 billion in the United States (US) dollars each year. Thirty-day hospital mortality associated with CAP has been estimated to be as high as 22% and is the leading cause of death amongst all infectious diseases.
Infection typically occurs after the colonization of the oropharynx and nasopharynx of healthy individuals. Inhalation of these colonies causes the infection of the lower airways. Infection, typically will not result unless a patient has predisposed risk factors, a bolus of infectious cells or due to a particularly virulent strain of S. pneumoniae.
The capsule plays a major role in the pathogenesis of Streptococcus pneumoniae. It is made up of polysaccharides and surrounds the cell wall. It helps in escaping phagocytosis by preventing the access of granulocytes to the underlying cell wall. These polysaccharides of the capsule help in the identification and serotyping of the bacteria. Many serotypes have been detected, 6, 14, 18, 19 and 23 are the most common ones causing the infection. On culture media, the virulence of these strains can be identified by their appearance, opaque and transparent types. Transparent type usually colonizes in nasopharynx while the opaque type is present in the lung, brain and bloodstream infection.
""Pneumococcal infections - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pneumococcal infections pipeline landscape is provided which includes the disease overview and Pneumococcal infections treatment guidelines. The assessment part of the report embraces, in depth Pneumococcal infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pneumococcal infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Pneumococcal infections. The therapies under development are focused on novel approaches to treat/improve Pneumococcal infections.
DWN12088: Daewoong Pharmaceutical
DWN12088 is an investigational therapy for idiopathic pulmonary fibrosis (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body’s ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein’s sequence. The FDA designated it as an orphan drug for idiopathic pulmonary fibrosis (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.
AFX3772: Affinivax
AFX3772, is a lead vaccine candidate targeting Streptococcus pneumoniae, includes 24 pneumococcal polysaccharides, more than any other vaccine on the market, as well as two conserved pneumococcal proteins. Developed using Affinivax’s proprietary MAPS™ (Multiple Antigen-Presenting System) technology platform, AFX3772 is designed to elicit both B-cell (antibody) and T-cell immune protection against Streptococcus pneumoniae. Company expect a Phase III clinical trial in older adults to begin in 2022. The clinical program targeting the infant pneumococcal indication has been initiated with an ongoing Phase 1 study in healthy toddlers 12 to 15 months of age.
PnuBioVax: ImmBio
nuBioVax, a vaccine targeting pneumococcal disease. This project, initiated with funding from the UK’s Biomedical Catalyst, has provided strong evidence of cross-strain efficacy beyond current vaccines. PnuBioVax has now progressed into full Clinical Development with the completion of a Phase I Clinical Trial.
Further product details are provided in the report……..
Pneumococcal infections: Therapeutic Assessment
This segment of the report provides insights about the Pneumococcal infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pneumococcal infections
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Pneumococcal infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pneumococcal infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pneumococcal infections drugs.
Pneumococcal infections Report Insights
- Pneumococcal infections Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pneumococcal infections drugs?
- How many Pneumococcal infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pneumococcal infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pneumococcal infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pneumococcal infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- Merck Sharp & Dohme Corp
- Vaxcyte
- Panacea Biotech
- EuBiologics
- Affinivax
- GangaGen
- ImmBio
- SK bioscience
- V 116
- VAX XP
- Pneumococcal vaccine conjugate 10-valent
- ASP 3772
- Pneumococcal conjugate vaccine
- MAPS30
- PnuBioVax
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
120 Pages
- Introduction
- Executive Summary
- Pneumococcal infections: Overview
- What is Pneumococcal infections?
- Types of Pneumococcal infections
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Pneumococcal infections– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ASP 3772: Affinivax
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Pneumococcal vaccine conjugate 10-valent: EuBiologics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- MAPS30: Affinivax
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Pneumococcal infections Key Companies
- Pneumococcal infections Key Products
- Pneumococcal infections- Unmet Needs
- Pneumococcal infections- Market Drivers and Barriers
- Pneumococcal infections- Future Perspectives and Conclusion
- Pneumococcal infections Analyst Views
- Pneumococcal infections Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
